, Tracking Stock Market Picks
Enter Symbol:

up 99.43 %

ONCOTHYREON (ONTY) rated Buy with price target $4 by H.C. Wainwright

Posted on: Tuesday,  Oct 21, 2014  8:25 AM ET by HC Wainwright

HC Wainwright rated Buy ONCOTHYREON (NASDAQ: ONTY) on 10/21/2014, when the stock price was $1.77. Since
then, ONCOTHYREON has gained 99.44% as of 01/14/2016's recent price of $3.53.
If you would have followed this HC Wainwright's recommendation on ONTY, you would have gained 99.43% of your investment in 450 days.

Oncothyreon Inc. (Oncothyreon) is a clinical-stage biopharmaceutical company. The Company focuses primarily on the development of therapeutic products for the treatment of cancer. The Company?s cancer vaccines are designed to stimulate the immune system to attack cancer cells, while its small molecule compounds are designed to inhibit the activity of specific cancer-related proteins. Oncothyreon?s lead product candidate is Stimuvax, which is a cancer vaccine in Phase III development for non-small cell lung cancer (NSCLC). Oncothyreon has an exclusive, worldwide license to Merck KGaA of Darmstadt, Germany (Merck KGaA), for the development, manufacture and commercialization of Stimuvax. Its pipeline of product candidates is consisted of cancer vaccines and small molecule candidates. The Company?s wholly owned subsidiaries include Oncothyreon Canada Inc., Biomira Management Inc., ProlX Pharmaceuticals Corporation, Biomira International Inc., Biomira BV and Oncothyreon Luxembourg.

HC Wainwright
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
10/21/2014 8:25 AM Buy
1.77 4.00
as of 8/27/2015
1 Week up  6.96 %
1 Month down  -9.94 %
3 Months up  74.75 %
1 YTD up  99.43 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy